Table 6

Characteristics of NY-ESO-1/LAGE-1 antibody-positive EOC patientsa

PatientStageTumor statusInitial clinical responseRecurrencedFollow-up duration (months)Current status
NY-ESO-1bLAGE-1c
1IIICNegativeNegativeCReNo12ANED
2IIICPositivePositiveCRNo44ANED
3IIICPositivePositiveCRYes36AWD
4IIICPositiveNAPRP15DOD
5IVPositivePositivePRP36AWD
6IIICPositiveNegativeCRNo16ANED
7IIICPositiveNegativePRP16AWD
8IIICPositiveNACRYes40AWD
9IIICPositiveNACRNo46ANED
10IIICPositiveNACRYes92ANED
11IIICPositiveNegativeCRYes96ANED
12IIICPositiveNACRYes90DOD
  • a All tumors tissues were serous and grade 3 histology, except tumor from patient 8, which was transitional cell histology. All patients had stage IIIC disease, except patient 5, with stage IV disease.

  • b NY-ESO-1 expression was determined by RT/PCR and/or IHC.

  • c LAGE-1 expression was determined by RT-PCR.

  • d Response to frontline surgery and chemotherapy.

  • e CR, complete response, ANED, alive, no evidence of disease; AWD, alive with disease; NA, undetermined LAGE-1 status; PR, partial response; P, persistence/progression; DOD, dead of disease.